ArticleInternational journal of ophthalmology2025
Conbercept combined with 577 nm subthreshold micropulse laser for diabetic macular edema.
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of different anti-VEGF agents combined with pars plana vitrectomy in proliferative diabetic retinopathy: a systematic review and network meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2026Pooled it
- Review
- Research advances in the translational application of anti-VEGF combined with subthreshold micropulse laser therapy for refractory diabetic macular edema.American journal of translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and safety of conbercept combined with 577 nm subthreshold micropulse laser (STML) for treatment of diabetic macular edema (DME).
methodsA retrospective study was conducted. From October 2022 to March 2024, 72 patients diagnosed with DME at the outpatient clinic were enrolled. The patients were divided into two groups: the simple group (treated with conbercept alone) and the combination group (treated with 577 nm STML combined with conbercept). The following itmes were compared between the two groups: best corrected visual acuity (BCVA), central macular thickness (CMT), foveal avascular zone (FAZ), vessel density of the superficial capillary plexus (SCP) and deep capillary plexus (DCP), retinal mean sensitivity (RMS), injection numbers, and the number of cases with adverse effects.
resultsThe mean age of patients was 57.13±8.76 (range 34-77)y with DR history of 0.89±0.55y. With the progression of treatment, both groups showed significant improvements in BCVA, CMT, DCP vessel density, and RMS compared to baselines (all,
conclusionConbercept combined with STML has better outcomes for treatment of DME and less intravitreal injections compared to conbercept monotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.